Skip to main content
    P

    Pmv Pharmaceuticals Inc (PMVP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.19
    -0.08 (-6.30%)

    Market Cap: $95.93M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pmv Pharmaceuticals Inc (PMVP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Pmv Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$77.74M, operating cash flow was -$73.58M and free cash flow was -$73.61M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$34.37M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $86.21M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Research and development$69.88M$58.53M$55.88M$51.99M$36.49M$23.93M$20.76M$13.85M
    Operating income-$86.21M-$85.45M-$80.13M-$77.04M-$58.29M-$34.94M-$26.64M-$18.89M
    Net income-$77.74M-$58.71M-$68.96M-$73.32M-$57.85M-$34.44M-$25.35M-$17.54M
    EBITDAN/AN/AN/AN/A-$56.97M-$34.62M-$26.20M-$18.22M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$1.62M
    Gross profit$0$0$0-$33.00K$0$0$0N/A$0$0$0-$359.00K
    Operating income-$20.06M-$18.88M-$19.02M-$19.24M-$22.52M-$22.88M-$21.56M-$25.17M-$21.89M-$20.17M-$18.22M-$18.90M
    Net income-$34.37M-$18.09M-$18.04M-$18.04M-$21.06M-$21.21M-$17.44M-$23.00M-$19.23M-$1.21M-$15.27M-$15.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $403.00K by $37.58M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$116.56M$191.29M$252.15M$270.31M$331.57M$365.53M$103.03M$63.46M
    Current assets$115.23M$175.66M$207.41M$247.01M$301.29M$364.76M$102.09M$62.24M
    Cash and equivalents$37.98M$40.88M$37.71M$108.30M$172.47M$361.42M$73.28M$30.31M
    Total liabilities$11.85M$15.21M$26.46M$24.28M$23.01M$6.41M$4.57M$109.60M
    Short-term debt$403.00K$352.00K$852.00K$528.00K$403.00KN/AN/AN/A
    Shareholder equity$104.71M$176.08M$225.69M$246.03M$308.56M$359.12M-$70.47M-$46.14M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$111.40M$82.07M$96.56M$116.56M$133.84M$152.85M$170.61M$191.29M$223.50M$237.54M$236.88M$252.15M
    Total liabilities$54.30M$10.57M$8.60M$11.85M$12.85M$12.25M$10.50M$15.21M$25.59M$23.22M$24.20M$26.46M
    Cash and equivalents$19.99M$12.47M$39.13M$37.98M$36.34M$44.13M$51.34M$40.88M$48.81M$48.53M$47.65M$37.71M
    Shareholder equity$57.11M$71.50M$87.97M$104.71M$121.00M$140.60M$160.11M$176.08M$197.91M$214.31M$212.68M$225.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$73.58M-$51.28M-$55.66M-$63.76M-$46.57M-$32.74M-$22.07M-$15.18M
    Capital expenditures$29.00K$655.00K$968.00K$7.98M$2.74M$148.00K$109.00K$452.00K
    Free cash flow-$73.61M-$51.94M-$56.63M-$71.74M-$49.31M-$32.89M-$22.17M-$15.63M
    Investing cash flow$70.17M$53.35M-$50.55M-$1.37M-$143.58M$27.91M$3.23M$21.69M
    Financing cash flow$505.00K$313.00K$35.58M$958.00K$2.02M$292.97M$61.80M$0
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$18.18M-$14.58M-$19.68M-$17.19M-$19.82M-$18.30M-$18.27M-$16.66M-$16.84M-$1.60M-$16.18M-$12.09M
    Capital expendituresN/AN/A$0$15.00K$1.00K$11.00K$4.00K$56.00K$1.00K$2.00K$600.00K$203.00K
    Free cash flowN/AN/A-$19.68M-$17.20M-$19.82M-$18.31M-$18.27M-$16.72M-$16.84M-$1.60M-$16.78M-$12.29M
    Last 12 quarters

    Frequently Asked Questions About PMVP

    What is Pmv Pharmaceuticals' annual revenue?

    Pmv Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Pmv Pharmaceuticals profitable?

    No. Pmv Pharmaceuticals reported net income of -$77.74M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PMVP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$73.58M minus capital expenditures of $29.00K produced free cash flow of -$73.61M.

    How much debt does Pmv Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $403.00K and cash and equivalents of $37.98M.